Temasek raised W895 billion $793 million from another partial sale in South Korean biopharmaceutical firm Celltrion on Monday, moving quickly to sell the shares shortly after the lockup period for its previous sale expired last month.
Through an accelerated bookbuild offering, Singapore’s sovereign wealth fund sold 3.63 million shares in the Korea-listed firm at W247,000 per share -- at the widest end of the marketed 5% to 8% discount range against the stock’s W268,500 Monday close.
Sources familiar with the situation said the transaction, which was made through Temasek’s subsidiary Ion Investments, was upsized from 3.39 million shares after being oversubscribed multiple ...
¬ Haymarket Media Limited. All rights reserved.
